Evidence map›Paper›PMID 29499037›Full record

ArticlePloS one2018

Immune responses to an early lytic cytomegalovirus antigen in systemic lupus erythematosus patients: T-cell responses, cytokine secretions and antibody status.

Anette Holck Draborg, Niclas Stefan Rasmussen, Janni Lisander Larsen, Charlotte Sværke Jørgensen, Noreen Sandhu, Kristin Skogstrand, Søren Jacobsen, Gunnar Houen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Anette Holck DraborgDepartment of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark.ORCID 0000-0003-2210-6335
Niclas Stefan RasmussenDepartment of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark.
Janni Lisander LarsenCopenhagen Lupus & Vasculitis Clinic, Centre for Rheumatology and Spine Disease, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark.
Charlotte Sværke JørgensenDepartment of Virus & Microbiological Special Diagnostics, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark.
Noreen SandhuCenter for Neonatal Screening, Department of Congenital Disorders, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark.
Kristin SkogstrandCenter for Neonatal Screening, Department of Congenital Disorders, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark.
Søren JacobsenCopenhagen Lupus & Vasculitis Clinic, Centre for Rheumatology and Spine Disease, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark.
Gunnar HouenDepartment of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark.
Statens Serum Institut · DKCopenhagen University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated immune responses to a lytic cytomegalovirus antigen (CMVpp52), and to a lytic human herpes virus (HHV) 6 antigen (HHV6p41), in systemic lupus erythematosus (SLE) patients and healthy controls (HCs), in order to clarify if the previously established impaired responses to Epstein-Barr virus (EBV) in SLE patients is a general defect in their responses against (all) HHVs. Multiplex Luminex technology results showed a normal induction of five quantified cytokines (interferon γ, interleukin(IL)12, IL17, IL10, and tumor necrosis factor α) in SLE patients compared to HCs upon stimulation with CMVpp52 and HHV6p41. However, flow cytometric results showed a reduced upregulation of the activation marker CD69 on T-cells from SLE patients (n = 17) compared to HCs (n = 17) upon stimulation with CMVpp52, indicating limited or defective CMVpp52-specific T-cells and/or poor antigen-presentation in SLE patients, and thereby possibly decreased control of the CMV infection. In conclusion, the dysfunctional immune response against EBV previously established in SLE patients does not seem to apply to the same degree regarding the immune responses against CMV or HHV6. Results designate that the main contributing HHV agent in development or exacerbation of SLE (in genetically predisposed individuals) is the previously determined uncontrolled EBV infection, and to a lesser extent CMV infection, and probably with no involvement of HHV6 infection.

Indexed as

AdultAgedAged, 80 and overAntibodies, ViralAntigens, CDAntigens, Differentiation, T-LymphocyteAntigens, ViralCase-Control StudiesCD69 AntigensCytokinesCytomegalovirusDNA-Binding ProteinsEnzyme-Linked Immunosorbent AssayFemaleHerpesvirus 6, HumanHumansAntibodies, ViralAntigens, CDAntigens, Differentiation, T-LymphocyteAntigens, ViralCD69 AntigensCytokinesDNA-Binding ProteinsImmediate-Early Proteinsimmediate-early proteins, cytomegalovirusLectins, C-Typep41 protein, Human herpesvirus 6Viral Proteins

Identifiers

PMID29499037
PMCPMC5834189
OpenAlexW2792230450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.